At Aegros we believe, access to life saving therapeutic plasma drugs is a human right and not a privilege. Our mission is to put the Patient 1st through the application of our unique ElectroSeparation process. Our Plasma Fractionation plant is in Macquarie Park and is currently being fitted out to manufacture a hyperimmune from Convalescent Covid-19 plasma called CovimmuneTM. Aegros will begin clinical trials in association with a Sydney major trauma hospital in October 2020.Covimmune: a hyperimmune to provide protection against Covid-19 for Front Line Healthcare Workers.

Website: aegros.com.au

Employees: 20 - 49

HQ: N/A

Location: NORTH PARRAMATTA, NSW, AU

Revenue: 2.5 - 5 Million

Are you looking for contact information for Aegros? Look no further than ConnectPlex.ai! Our comprehensive database contains company information for millions of companies worldwide, including Aegros. Our AI-based B2B lead generation products are designed to help you quickly and easily find the contact information you need to connect with people working in Aegros. With our keyword-rich content, you can be sure that our page will rank high in search engines for search terms like 'contact details for Aegros', making it easy for you to find the information you need. At ConnectPlex.ai, we understand the importance of having access to accurate and up-to-date contact information. That's why we're committed to providing you with the most reliable and efficient way to connect with people working in Aegros. Our user-friendly interface and powerful search tools make it easy for you to find the contact information you need in no time. So why wait? Start your search for Aegros contact information today and see the difference that ConnectPlex.ai can make for your business!

Aegros: Revolutionizing Therapeutic Plasma Production Aegros is a cutting-edge biotech company based in North Parramatta, Australia, with a mission to make life-saving therapeutic plasma drugs accessible to all. Founded in 2020, the company is dedicated to putting patients first through the application of its unique ElectroSeparation process. Aegros' state-of-the-art Plasma Fractionation plant, located in Macquarie Park, is currently being fitted out to manufacture CovimmuneTM, a hyperimmune derived from Convalescent Covid-19 plasma. The company's commitment to innovation and patient care is reflected in its partnership with a major trauma hospital in Sydney, where clinical trials for CovimmuneTM are set to begin in October 2020. This groundbreaking therapy has the potential to provide much-needed protection against Covid-19 for front-line healthcare workers, and Aegros is at the forefront of this pioneering research. Led by a team of experienced executives, including Managing Director and Co-Founder John Manusu, Group Chief Financial Officer Alex Anziif, and Chief Executive Officer Damian Thornton, Aegros is poised to revolutionize the therapeutic plasma industry. With a focus on quality, safety, and patient-centricity, the company is set to make a significant impact in the lives of countless individuals.

At Aegros, we believe that everyone should have access to life-saving medicines, regardless of their financial situation. Our goal is to make sure that patients come first, and we're working hard to make this happen. We have a special way of making medicines called ElectroSeparation, which we're using to create a medicine called CovimmuneTM. This medicine is made from the plasma of people who have recovered from Covid-19, and it's designed to help protect front-line healthcare workers from getting sick. We're setting up a plant in Macquarie Park to make this medicine, and we're planning to start testing it in clinical trials with a hospital in Sydney soon. We're excited to see how it can help keep healthcare workers safe!